XML 37 R24.htm IDEA: XBRL DOCUMENT
v3.22.4

OTHER EXPENSE, NET | 12 Months Ended
--- | ---
Dec. 31, 2022
Other Income and Expenses [Abstract] |
OTHER EXPENSE, NET | OTHER EXPENSE, NET Other expense, net for the years 2022, 2021 and 2020 consists of:
(in millions) |  | 2022 |  | 2021 |  | 2020
Litigation and other matters |  | $ | 9 |  |  | $ | 356 |  |  | $ | 422 |
Acquired in-process research and development costs |  | 1 |  |  | 8 |  |  | 32 |
Net gain on sale of assets |  | (5) |  |  | (2) |  |  | (1) |
Acquisition-related contingent consideration |  | 29 |  |  | 11 |  |  | 48 |
Other, net |  | 1 |  |  | — |  |  | 1 |
Other expense, net |  | $ | 35 |  |  | $ | 373 |  |  | $ | 502 |
In 2021, Litigation and other matters of $356 million includes adjustments related to the Glumetza Antitrust Litigation, partially offset by insurance recoveries related to certain litigation matters. In 2020, Litigation and other matters of $422 million includes net charges related to the U.S. Securities Litigation, the SEC Investigation and the Canadian Securities Litigation and related opt-outs. In 2020, Litigation and other matters also includes an insurance recovery related to a certain litigation matter. Certain of these matters and other significant matters are discussed in further detail in Note 20, “LEGAL PROCEEDINGS”. Net gain on sales of assets includes $25 million related to the achievement of a milestone related to a certain product and a $26 million loss upon completion of the Amoun Sale during 2021. In 2020, Acquired in-process research and development costs of $32 million, primarily consist of costs associated with the upfront payments to enter into certain exclusive licensing agreements.

X
- References No definition available. + Details
Name: | us-gaap_OtherIncomeAndExpensesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 720 -URI https://asc.fasb.org/topic&trid=2122503 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 610 -URI https://asc.fasb.org/topic&trid=49130413 + Details
Name: | us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration